Charles Schwab Investment Management Inc. lifted its position in shares of Simulations Plus, Inc. (NASDAQ:SLP - Free Report) by 16.2% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 166,392 shares of the technology company's stock after buying an additional 23,139 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.83% of Simulations Plus worth $4,080,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Fifth Third Bancorp lifted its holdings in shares of Simulations Plus by 33.8% during the first quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company's stock worth $36,000 after buying an additional 375 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Simulations Plus by 42.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company's stock worth $72,000 after buying an additional 764 shares in the last quarter. US Bancorp DE lifted its holdings in shares of Simulations Plus by 15.6% during the first quarter. US Bancorp DE now owns 6,576 shares of the technology company's stock worth $161,000 after buying an additional 889 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Simulations Plus during the first quarter worth $210,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Simulations Plus by 4.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,103 shares of the technology company's stock worth $254,000 after buying an additional 380 shares in the last quarter. Institutional investors and hedge funds own 78.08% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on SLP shares. BTIG Research dropped their target price on Simulations Plus from $41.00 to $25.00 and set a "buy" rating for the company in a report on Monday, July 7th. Craig Hallum dropped their target price on Simulations Plus from $45.00 to $36.00 and set a "buy" rating for the company in a report on Friday, June 13th. Zacks Research raised shares of Simulations Plus to a "hold" rating in a report on Tuesday, August 12th. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a report on Tuesday, July 15th. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Simulations Plus in a report on Wednesday, June 18th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $26.50.
Get Our Latest Stock Report on Simulations Plus
Simulations Plus Trading Down 0.1%
NASDAQ SLP traded down $0.01 during trading on Wednesday, hitting $14.38. 246,495 shares of the company's stock were exchanged, compared to its average volume of 363,392. The company has a market cap of $289.47 million, a PE ratio of -4.57 and a beta of 0.85. Simulations Plus, Inc. has a fifty-two week low of $12.39 and a fifty-two week high of $37.67. The stock's 50 day moving average price is $14.67 and its two-hundred day moving average price is $23.63.
Simulations Plus (NASDAQ:SLP - Get Free Report) last issued its earnings results on Monday, July 14th. The technology company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.26 by $0.19. The firm had revenue of $20.36 million during the quarter, compared to the consensus estimate of $22.83 million. Simulations Plus had a positive return on equity of 11.62% and a negative net margin of 78.63%.The business's quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.27 earnings per share. Analysts forecast that Simulations Plus, Inc. will post 1.09 earnings per share for the current fiscal year.
Simulations Plus Profile
(
Free Report)
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Featured Articles

Before you consider Simulations Plus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Simulations Plus wasn't on the list.
While Simulations Plus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.